For 2003, non-cash activities included the allocation of $6.1 million of other assets and $12.8 million in certain intangible contract- based product marketing and other rights to the purchase price for the acquisitions of Oculex Pharmaceuticals, Inc., and Bardeen Sciences Company, LLC, respectively. Additionally, the Company recorded a dividend (dividend adjustment) in the amount of $(0.3) million and $53.2 million in 2003 and 2002, respectively, related to the distribution of Advanced Medical Optics, Inc.’s common stock to the Company’s stockholders. CASH FLOWS FROM FINANCING ACTIVITIES Dividends to stockholders $ (46.9) $ (46.7) $ (47.5) Increase (decrease) in notes payable 10.0 (11.8) (12.3) Sale of stock to employees 47.0 24.4 30.9 Net borrowings under commercial paper obligations 10.4 – – Proceeds from convertible borrowings – 500.0 – Repayments of convertible borrowings (46.2) (376.5) – Debt issuance costs – (12.1) – Repayments of long-term debt (0.5) (25.6) (3.2) Payments to acquire treasury stock  (90.6) (180.8) (130.9) Net cash used in financing activities (116.8) (129.1) (163.0) Cash flow from discontinued operations – 172.0 56.3 Effect of exchange rates on cash and equivalents 10.0 (11.8) (4.9) Net (decrease) increase in cash and equivalents (266.4) (0.9) 13.6 Cash and equivalents at beginning of year 774.0 774.9 761.3 Cash and equivalents at end of year $507.6 $774.0 $774.9 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid during the year for: Interest (net of amount capitalized) $ 15.7 $ 14.8 $ 20.9 Income taxes, net of refunds $ 72.3 $ 85.6 $ 52.2 Year ended December 31, In millions 2003 2002 2001